Market revenue in 2023 | USD 2,228.1 million |
Market revenue in 2030 | USD 3,897.6 million |
Growth rate | 8.3% (CAGR from 2023 to 2030) |
Largest segment | Clinical |
Fastest growing segment | Preclinical |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Discovery, Preclinical, Clinical |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Drug Development, Pharmaceutical Product Development, PAREXEL, Charles River Laboratories International Inc, Icon PLC, Medidata, Syneos Health, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Wuxi AppTec Co Ltd, Medpace Holdings Inc, CTI Clinical Trial and Consulting Services, Eurofins Scientific SE |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dermatology cro market will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 75.83% in 2023. Horizon Databook has segmented the Asia Pacific dermatology cro market based on drug discovery, preclinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific dermatology cro market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific dermatology cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account